UNSPSC 51294422: Vilazodone hydrochloride

This classification denotes a serotonin agonist and antidepressant agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier U8HTX2GK8J. European Medicines Agency schedules Vilazodone hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB32288. Vilazodone hydrochloride generally arises in the molecular formula C26H27N5O2.CLH. The term 'vilazodone hydrochloride' is a United States Adopted Name designation.

Most nations, for tariff and trade purposes, schedule vilazodone hydrochloride under HS 29349990 and SITC 51579. As of Q4 2014, VILAZODONE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Vilazodone hydrochloride bears US NLM identifiers UMLS ID C0539286 and NCI Concept Code C90717. SMILES: C1CC2C(CC1C#N)C(C[NH]2)CCCCN3CCN(CC3)C4CCC5C(C4)CC(O5)C(=O)N.CL.

UNSPSC 51294422 Vilazodone hydrochloride is a Commodity code that nominally describes a specific antidepressant pharmaceutical, but recent state and local procurement activity under this code shows little alignment with that scope. The most recent opportunities tagged to this code involve naloxone procurement, direct-to-manufacturer pharmacy initiatives, and multi-source generic pharmaceuticals through cooperative purchasing — none of which are vilazodone-specific or antidepressant-focused. The mismatch suggests either miscoding in state and local procurement systems or that this code functions as a placeholder for broader pharmaceutical acquisition rather than the named active ingredient. Issuing bodies include county health departments (Seminole County, Florida), state health and human services commissions (Texas HHS Commission), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP). No repeat buyers appear in the recent opportunity set, and no set-aside or preference designations are reported across the three solicitations.

Geographic activity centers on Florida, Texas, and Minnesota, with MMCAP's multistate reach extending to Oregon and other participating jurisdictions. The three representative recent opportunities span different procurement mechanisms and timelines: Seminole County issued IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with a July 26, 2023, response deadline; the Texas HHS Commission posted RFI HHS0017013 on April 3, 2026, as a market-intelligence inquiry regarding direct-to-manufacturer prescription fulfillment capability; and MMCAP issued an RFP (S1070000015802) on January 20, 2026, for generic multi-source pharmaceuticals and OTC products, with a March 26, 2026, proposal deadline and July 1, 2026, contract effective date. The code shows limited recent activity with clear relevance to the vilazodone product name.